Step 1
Draft
Step 2
Unite with Fellow Investors
Step 3
Choose the Best Attorney
Step 4
Provide Documents
Step 5
Follow Case Progress
Step 6
Get Payout
REPH.US
id: 334
The settlement funds have been distributed to claimants.
$1,400,000
Cash SettlementE.D. Pennsylvania
Court07/17/2017
Class period Start05/23/2018
Class period End10/08/2022
Claim deadlineRecro Pharma agreed to pay $1.4 million to settle a securities class action lawsuit accusing the Company of deceiving investors about material information.
The original complaint alleged that the Company and its Leaders misled investors through a series of public statements regarding Recro’s target opportunities that allegedly inflated Recro’s stock price, in particular, they misrepresented and/or omitted Key Opinion Leader concerns about the drug IV meloxicam.
Recro Pharma agreed to settle with investors to avoid further litigation.
Case Status
Disbursed
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Plaintiffs
John Alberici
Attorneys
Pomerantz LLP, Kaskela Law LLC, Bronstein, Gewirtz & Grossman LLC
Judge
Hon. Michael M. Baylson
Administrator
Strategic Claims Services
Court hearing date
10/26/2022
Trades matching type
FIFO
Disbursement date
04/21/2023
Trusted by industry leaders
Endorsed by top professionals who trust our innovative solutions to drive impactful results.